11/30/2021

PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

TORONTO, November 30, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Japan Patent Office has issued Japanese Patent No. 6967532 for KETABET™, a combination formulation of FDA-approved ketamine and betaine anhydrous, which has shown in research to enhance the antidepressant effect while having the potential to reduce the known negative side effects of ketamine significantly. The granted patent strengthens the Company’s global patent portfolio and it provides for broad potential of KETABET™ for uses in various mental health, neurological and pain disorders, as well as novel delivery forms such as with the Company’s patented hydrogel-forming microneedle patch delivery system.

11/24/2021

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndrome
Strengthens commitment to treat rare disorders and life-threatening conditions with ketamine

11/11/2021

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness.
Completing microneedle patch research programs with other psychedelics before year-end.
Pursuing Phase 2 clinical studies in 2022 with psilocybin and notable psychedelics.

11/3/2021

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

Focusing on partnership model for MicroDose-MN™ and MacroDose-MN™ patches to deliver psychedelics.
Creating value and intellectual property protection for psychedelic programs.
Providing pathways for partners to enter FDA Phase 1 and 2 clinical studies in 2022 with psychedelics.

11/1/2021

PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics

Completing IND-enabling studies with novel microneedle patch for ketamine, psilocybin, MDMA, LSD, and DMT.
Expanding research in evaluating ibogaine and mescaline.
Aiming for FDA Phase 1 and 2 clinical studies in Q2-2022.
Discussing partnership opportunities for delivering psychedelics with MicroDose-MN™ and MacroDose-MN™ patches.

10/27/2021

PharmaTher Provides Busines Update and Releases Financial Results for the First Quarter of Fiscal 2022

TORONTO, October 27, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released its business update and financial results for the three months ended August 31, 2021. All amounts are stated in Canadian dollars unless otherwise indicated.

10/27/2021

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

Focus on expanding the delivery of controlled-substances in a microneedle patch.
Evaluating potential uses of a microneedle patch for infectious diseases.
Strengthening capabilities in the manufacturing of microneedle patches for FDA clinical studies and commercialization.

10/19/2021

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.
Expected FDA clinical and commercial supply in H2-2022.
Unlocking potential partnership opportunities with research labs, clinics and pharmaceutical companies globally.

10/13/2021

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

Achieving its second FDA orphan drug designation with ketamine.
Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation.
Seeking to enter Phase 2 clinical trial in 2022.

10/6/2021

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

“KET-LID” trial to evaluate ketamine’s safety and efficacy in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease

TORONTO, October 6, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial of Ketamine for the treatment of Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease. Patient screening and enrollment is expected to begin in October 2021 with data anticipated in late-Q4 2021.

Press Releases